title: [Effect of interferon-alpha on the prognosis of bone marrow transplantation in chronic myeloid leukemia].
abstract: OBJECTIVE
  To investigate whether prior interferon alfa (IFN-alpha) treatment affects the outcome of allogeneic bone marrow transplantation.
  
  
  METHODS
  The outcome of 85 patients with chronic myelogenous leukemia (CML) in first chronic phase received transplants from an HLA-identical sibling donor was analyzed. Of the 85 patients, 30 did not receive IFN-alpha, whereas 30, 15 and 10 patients received IFN-alpha 3 x 10(6) units 3-4 times per week for < 6, 6-12 and > 12 months before transplant combined with hydroxyurea and/or HA regimen (H: Harringtonine; A: Ara-C) respectively.
  
  
  RESULTS
  Pretransplant IFN-alpha therapy for > or = 6 months was associated with an increased risk of severe (grade III-IV) acute graft-versus-host disease (GVHD) (P < 0.01) as compared to that in < 6 months or no IFN-alpha therapy. No influence of pretransplant IFN-alpha treatment on engraft, cGVHD, VOD, relapse and TRM (transplant-related mortality) was found. Survival rate of IFN-alpha therapy < 6 months group (90.0%) was higher than that of no IFN-alpha group (68.9%) or > 12 months group(60.0%) (P < 0.05).
  
  
  CONCLUSIONS
  It was found that there was a trend towards an improved survival in the IFN-alpha < 6 months group. Pretransplant IFN-alpha therapy for > or = 6 months was associated with an increased risk of severe aGVHD.
authors.affiliation: Institute of Hematology, People's Hospital, Beijing University, Beijing 100044, China.
authors.forename: L
authors.initials: L
authors.lastname: Xu
authors.forename: N
authors.initials: N
authors.lastname: Guo
authors.forename: X
authors.initials: X
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D006086:Graft vs Host Disease / Q000139:chemically induced*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care / Q000009:adverse effects*; D011379:Prognosis; D012044:Regression Analysis; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D016898:Interferon-alpha